The immunoinformatics of cancer immunotherapy.

We review here the developments in the field of immunoinformatics and their present and potential applications to the immunotherapeutic treatment of cancer. Antigen presentation plays a central role in the immune response, and as a result in immunotherapeutic methods such as adoptive T-cell transfer and antitumor vaccination. We therefore extensively review the current technologies of antigen presentation prediction, including the next generation predictors, which combine proteasomal processing, transporter associated with antigen processing and major histocompatibility complex (MHC)-binding prediction. Minor histocompatibility antigens are also relevant targets for immunotherapy, and we review the current systems available, SNEP and SiPep. Here, antigen presentation plays a key role, but additional types of data are also incorporated, such as single nucleotide polymorphism data and tissue/cell-type expression data. Current systems are not capable of handling the concept of immunodominance, which is critical to immunotherapy, but efforts have been made to model general aspects of the immune system. Although tough challenges lie ahead, when measuring the field of immunoinformatics on its contributions thus far, one can expect fruitful developments in the future.

[1]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[2]  A. Varshavsky,et al.  In vivo half-life of a protein is a function of its amino-terminal residue. , 1986, Science.

[3]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[4]  R. Tampé,et al.  The Intracellular Antigen Transport Machinery TAP in Adaptive Immunity and Virus Escape Mechanisms , 2005, Journal of bioenergetics and biomembranes.

[5]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[6]  E. Celis,et al.  Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. , 2000, Cancer research.

[7]  Darren R Flower,et al.  Class I T-cell epitope prediction: improvements using a combination of proteasome cleavage, TAP affinity, and MHC binding. , 2006, Molecular immunology.

[8]  D. Zaller,et al.  Prediction of peptide affinity to HLA DRB1*0401. , 1994, International archives of allergy and immunology.

[9]  S Brunak,et al.  Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.

[10]  C. Yee.  Journal of Translational Medicine Adoptive T Cell Therapy: Addressing Challenges in Cancer Immunotherapy , 2005 .

[11]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[12]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[13]  S Uebel,et al.  Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Cheever,et al.  HER-2/neu oncogenic protein: issues in vaccine development. , 1998, Critical reviews in immunology.

[15]  Pingping Guan,et al.  EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.

[16]  Stephanie Forrest,et al.  Infect Recognize Destroy , 1996 .

[17]  O. Lund,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[18]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[19]  A Sette,et al.  Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.

[20]  A Sette,et al.  The peptide-binding motif for the human transporter associated with antigen processing , 1995, The Journal of experimental medicine.

[21]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[22]  Vladimir Brusic,et al.  Immunoinformatics--the new kid in town. , 2003, Novartis Foundation symposium.

[23]  A. Goldberg,et al.  Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Oliver Kohlbacher,et al.  SNEP: SNP-derived Epitope Prediction program for minor H antigens , 2005, Immunogenetics.

[25]  F. Ginhoux,et al.  Quantifying Recruitment of Cytosolic Peptides for HLA Class I Presentation: Impact of TAP Transport1 , 2003, The Journal of Immunology.

[26]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[27]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[28]  D Rognan,et al.  Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. , 1994, Biochemistry.

[29]  E. Warren,et al.  A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion , 2003, The Journal of experimental medicine.

[30]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[31]  R. Huber,et al.  Structure of 20S proteasome from yeast at 2.4Å resolution , 1997, Nature.

[32]  O. Lund,et al.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.

[33]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[34]  L. Hambach,et al.  Immunotherapy of cancer through targeting of minor histocompatibility antigens. , 2005, Current opinion in immunology.

[35]  S. H. van der Burg,et al.  Design and evaluation of antigen-specific vaccination strategies against cancer. , 2000, Current opinion in immunology.

[36]  J. Stark,et al.  Analysis of cytokine dynamics in corneal allograft rejection , 1999, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[37]  Rachelle Gaudet,et al.  Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing , 2001, The EMBO journal.

[38]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Knutson,et al.  Adoptive T cell therapy of solid cancers , 2005, Cancer Immunology, Immunotherapy.

[40]  Ilan Beer,et al.  Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor‐specific antigens , 2002, European journal of immunology.

[41]  D. DeLuca,et al.  A modular concept of HLA for comprehensive peptide binding prediction , 2006, Immunogenetics.

[42]  D. Moss,et al.  SiPep: a system for the prediction of tissue‐specific minor histocompatibility antigens , 2006, International journal of immunogenetics.

[43]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[44]  Hans-Georg Rammensee,et al.  The Human 26 S and 20 S Proteasomes Generate Overlapping but Different Sets of Peptide Fragments from a Model Protein Substrate* , 2000, The Journal of Biological Chemistry.

[45]  P. van Endert,et al.  Substrate selection by transporters associated with antigen processing occurs during peptide binding to TAP. , 1998, Molecular immunology.

[46]  Robert Tampé,et al.  The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. , 2004, Physiology.

[47]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[48]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[49]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[50]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[51]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[52]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[53]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[54]  Kun Yu,et al.  Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.

[55]  Ferry Ossendorp,et al.  Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[56]  D. Rognan,et al.  Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. , 1999, Journal of medicinal chemistry.

[57]  J. Thompson,et al.  Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. , 1996, Journal of immunology.

[58]  J. Madrigal,et al.  Progress made towards the development of a CMV peptide vaccine. , 2004, Human immunology.

[59]  U. Koszinowski,et al.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein , 1991, Cell.

[60]  Gajendra P.S. Raghava,et al.  A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.

[61]  Hans-Georg Rammensee,et al.  Quantitative Analysis of Prion-Protein Degradation by Constitutive and Immuno-20S Proteasomes Indicates Differences Correlated with Disease Susceptibility1 , 2004, The Journal of Immunology.

[62]  D. Wiley,et al.  The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.

[63]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[64]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[65]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[66]  P. Kloetzel,et al.  Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding , 2005, Cellular and Molecular Life Sciences CMLS.

[67]  N. Shastri,et al.  ER aminopeptidases generate a unique pool of peptides for MHC class I molecules , 2001, Nature Immunology.

[68]  A. Barrett,et al.  10 Graft-versus-leukaemia , 1997 .

[69]  Shelley L. Hemsley,et al.  Transporter Associated with Antigen Processing Preselection of Peptides Binding to the MHC: A Bioinformatic Evaluation , 2004, The Journal of Immunology.

[70]  E. Holler,et al.  Adoptive immunotherapy with donor lymphocyte transfusions. , 1997, Current opinion in oncology.

[71]  Channa K. Hattotuwagama,et al.  MHCPred 2.0 , 2006 .

[72]  Antoni Ribas,et al.  Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Bjoern Peters,et al.  Identifying MHC Class I Epitopes by Predicting the TAP Transport Efficiency of Epitope Precursors , 2003, The Journal of Immunology.